Aerovate Therapeutics saw the highest growth of 1.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Aerovate Therapeutics’s patent filings and grants. Buy the databook here.
Aerovate Therapeutics has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent filings with nearly 100% of filings. The United States(US) patent Office are among the top ten patent offices where Aerovate Therapeutics is filings its patents..
Roche and Johnson & Johnson could be the strongest competitors for Aerovate Therapeutics
Patents related to rare diseases lead Aerovate Therapeutics's portfolio
Aerovate Therapeutics has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Leukemia related patents lead Aerovate Therapeutics portfolio followed by cardiovascular, and pulmonary hypertension
Aerovate Therapeutics has highest number of patents in leukemia followed by cardiovascular, pulmonary hypertension, pulmonary arterial hypertension, and dental caries.
For comprehensive analysis of Aerovate Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.